anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

Table

Component collection for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Matching slides 60,568
Current window 44,371-44,400
Pages 2,019
Rows per page 30
Component: Tableclear collectionreset all
18 30 60

Component

44,371-44,400 of 60,568

filter-aware
33
The table highlights superior response rates (100% ORR, 70% CR) for NXC-201 compared to competitors.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Evidence & Proof1 hit
34
The table uses a red dashed box to highlight key clinical efficacy and safety metrics (ORR, CR, ICANS, CRS).Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Evidence & Proof1 hit
36
The slide uses a two-column layout to contrast clinical outcomes for two different indications, followed by a row of competitor product logos and financial metrics.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Evidence & Proof1 hit
43
The table displays clinical trial data for NXC-201, specifically focusing on Cytokine Release Syndrome (CRS) and Immune cell associated Neurotoxicity (ICANS) across three dosage groups.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Impact & Next Steps1 hit
44
The table highlights specific adverse events (CRS and ICANS) within a red dashed box.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Impact & Next Steps1 hit
45
Highlights NXC-201's lower fludarabine dose (25 mg vs 30 mg) and Carvykti's longer infusion window (5-7 days vs 5 days).Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Impact & Next Steps1 hit
46
Immix Biopharma | Investor Presentation Deck | 64 slidesImmix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Impact & Next Steps1 hit
47
Immix Biopharma | Investor Presentation Deck | 64 slidesImmix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Impact & Next Steps1 hit
53
The slide uses a scatter plot to map clinical trials and a table to detail standard-of-care metrics by line of therapy.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Impact & Next Steps1 hit
54
The slide compares clinical outcomes for patients across different lines of treatment, emphasizing high disease control and zero drug-related toxicity.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Impact & Next Steps1 hit
04
Independent Bank Corp | Results Presentation Deck | 30 slidesIndependent Bank Corp | Results Presentation Deck | 30 slides · Independent Bank Corp
Conference presentation Investor relations Beat · Problem1 hit
13
The slide presents a sensitivity analysis of NII to interest rate shifts, comparing Dec 31 2023 and Sep 30 2023.Independent Bank Corp | Results Presentation Deck | 30 slides · Independent Bank Corp
Conference presentation Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
16
The slide uses a before-after framing to compare initial outlooks (as of Jan 2023) with year-end results.Independent Bank Corp | Results Presentation Deck | 30 slides · Independent Bank Corp
Conference presentation Investor relations Beat · Market Size1 hit
17
The slide uses a before-after framing to compare initial outlooks with year-end results.Independent Bank Corp | Results Presentation Deck | 30 slides · Independent Bank Corp
Conference presentation Investor relations Beat · Market Size1 hit
18
The slide uses a three-column layout to categorize financial projections.Independent Bank Corp | Results Presentation Deck | 30 slides · Independent Bank Corp
Conference presentation Investor relations Beat · Market Size1 hit
19
The slide uses a table-like layout to present forward-looking guidance for the fiscal year 2024.Independent Bank Corp | Results Presentation Deck | 30 slides · Independent Bank Corp
Conference presentation Investor relations Beat · Market Size1 hit
23
The table contains a likely data entry error in the 6/30/23 column for capital ratios (0.1% for all four metrics).Independent Bank Corp | Results Presentation Deck | 30 slides · Independent Bank Corp
Conference presentation Investor relations 1 hit
24
Includes 5-year CAGR for select metrics. Data is presented in millions except for per share data.Independent Bank Corp | Results Presentation Deck | 30 slides · Independent Bank Corp
Conference presentation Investor relations 1 hit
25
Includes a table of liquidity sources and a grouped bar chart showing coverage ratios.Independent Bank Corp | Results Presentation Deck | 30 slides · Independent Bank Corp
Conference presentation Investor relations 1 hit
28
The slide title refers to 'Non-GAAP to GAAP Reconciliation', but the content is a standard financial summary table.Independent Bank Corp | Results Presentation Deck | 30 slides · Independent Bank Corp
Conference presentation Investor relations 1 hit
29
Standard financial disclosure slide for non-GAAP metrics.Independent Bank Corp | Results Presentation Deck | 30 slides · Independent Bank Corp
Conference presentation Investor relations 1 hit
30
The table provides a breakdown of common shareholders' equity and total assets, subtracting goodwill and other intangibles to arrive at tangible measures.Independent Bank Corp | Results Presentation Deck | 30 slides · Independent Bank Corp
Conference presentation Investor relations 1 hit
08
Includes a bar chart for CASM growth and a table for ASM growth, alongside bulleted strategic updates.jetBlue | Results Presentation Deck | 17 slides · JetBlue
Conference presentation Investor relations Beat · SatisfactionLoop · Cost Of Inaction1 hit
10
Includes footnotes regarding non-GAAP measures, pilot union agreement impacts, and fuel price assumptions.jetBlue | Results Presentation Deck | 17 slides · JetBlue
Conference presentation Investor relations Beat · SatisfactionLoop · Cost Of Inaction1 hit
13
Includes reconciliation of CASM to CASM Ex-Fuel.jetBlue | Results Presentation Deck | 17 slides · JetBlue
Conference presentation Investor relations Beat · Action1 hit
14
The slide provides a detailed breakdown of adjustments for Spirit costs, union contract costs, and fleet transition costs.jetBlue | Results Presentation Deck | 17 slides · JetBlue
Conference presentation Investor relations Beat · Action1 hit
15
This is a continuation slide for a non-GAAP financial reconciliation.jetBlue | Results Presentation Deck | 17 slides · JetBlue
Conference presentation Investor relations Beat · Action1 hit
05
The slide uses a red box to highlight the 4Q23 column and a callout box to explain the EPS impact.KeyCorp | Results Presentation Deck | 30 slides · KeyCorp
Conference presentation Investor relations Beat · EvidenceLoop · Logic Chain1 hit
09
KeyCorp | Results Presentation Deck | 30 slidesKeyCorp | Results Presentation Deck | 30 slides · KeyCorp
Conference presentation Investor relations Beat · EvidenceLoop · Logic Chain1 hit
10
The slide uses a table to show expense categories and callouts to explain specific 'select items' impacting the variance.KeyCorp | Results Presentation Deck | 30 slides · KeyCorp
Conference presentation Investor relations Beat · EvidenceLoop · Logic Chain1 hit